Aligos Therapeutics, Inc.
ALGS
Rank in Stocks
#25646
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-Γ agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Share Price
$3.95
Last synced: 2026-11-09
Market Cap
$24.67M
Change (1 day)
-2.95%
Change (1 year)
-40.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Aligos Therapeutics, Inc. (ALGS)
Category
Healthcare
EPS for Aligos Therapeutics, Inc. (ALGS)
EPS as of September 2026 TTM: $-6.35
According to Aligos Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-6.35. At the end of 2025 the company had an EPS of $-2.45, an increase over its 2024 EPS of $-20.94.
EPS history for Aligos Therapeutics, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-6.35 | 159.18% |
| 2025 | $-2.45 | -88.30% |
| 2024 | $-20.94 | 494.89% |
| 2023 | $-3.52 | 56.44% |
| 2022 | $-2.25 | -30.12% |
| 2021 | $-3.22 | 1.26% |
| 2020 | $-3.18 | 33.61% |
| 2019 | $-2.38 | 260.61% |
| 2018 | $-0.66 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -346.61% |
US
|
|
| $-7.07 | 11.34% |
US
|
|
| $-5.29 | -16.69% |
AU
|
|
| $12.88 | -302.84% |
BE
|
|
| $21.56 | -439.53% |
NL
|
Questions about Aligos Therapeutics, Inc.'s earnings per share (EPS)
What is Aligos Therapeutics, Inc.'s earnings per share (EPS)?
Aligos Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-6.35, as of Sep 2026.
What was Aligos Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Aligos Therapeutics, Inc.'s earnings per share (EPS) was $-2.45, compared with $-20.94 in 2024.
How has Aligos Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Aligos Therapeutics, Inc.'s earnings per share (EPS) was highest in 2022 ($-2.25) and lowest in 2024 ($-20.94).
How does Aligos Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Aligos Therapeutics, Inc.'s earnings per share (EPS) ($-6.35) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.